FI20116138L - Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen - Google Patents
Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen Download PDFInfo
- Publication number
- FI20116138L FI20116138L FI20116138A FI20116138A FI20116138L FI 20116138 L FI20116138 L FI 20116138L FI 20116138 A FI20116138 A FI 20116138A FI 20116138 A FI20116138 A FI 20116138A FI 20116138 L FI20116138 L FI 20116138L
- Authority
- FI
- Finland
- Prior art keywords
- matrix
- controlled release
- bioactive substances
- bioactive
- substances
- Prior art date
Links
- 230000000975 bioactive effect Effects 0.000 title 1
- 238000013270 controlled release Methods 0.000 title 1
- 239000011159 matrix material Substances 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20116138A FI130619B (fi) | 2011-11-15 | 2011-11-15 | Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen |
PCT/FI2012/051121 WO2013072563A1 (en) | 2011-11-15 | 2012-11-15 | Drug delivery system for sustained delivery of bioactive agents |
EP12799232.9A EP2779996B1 (en) | 2011-11-15 | 2012-11-15 | Drug delivery system for sustained delivery of bioactive agents |
US14/358,141 US11389537B2 (en) | 2011-11-15 | 2012-11-15 | Drug delivery system for sustained delivery of bioactive agents |
JP2014541721A JP6178329B2 (ja) | 2011-11-15 | 2012-11-15 | 生物活性剤の持続性送達のためのドラッグデリバリーシステム |
HK15102889.3A HK1202418A1 (en) | 2011-11-15 | 2015-03-23 | Drug delivery system for sustained delivery of bioactive agents |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20116138A FI130619B (fi) | 2011-11-15 | 2011-11-15 | Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen |
Publications (2)
Publication Number | Publication Date |
---|---|
FI20116138L true FI20116138L (fi) | 2013-05-16 |
FI130619B FI130619B (fi) | 2023-12-15 |
Family
ID=47351708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI20116138A FI130619B (fi) | 2011-11-15 | 2011-11-15 | Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen |
Country Status (6)
Country | Link |
---|---|
US (1) | US11389537B2 (fi) |
EP (1) | EP2779996B1 (fi) |
JP (1) | JP6178329B2 (fi) |
FI (1) | FI130619B (fi) |
HK (1) | HK1202418A1 (fi) |
WO (1) | WO2013072563A1 (fi) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI125942B (fi) | 2013-07-26 | 2016-04-15 | Upm Kymmene Corp | Nanofibrilliselluloosakoostumuksen modifiointimenetelmä |
FI126120B (fi) | 2014-12-22 | 2016-06-30 | Upm Kymmene Corp | Prosessi hapetetun nanofibrilliselluloosan hydrogeelin tuottamiseksi |
FI125882B (fi) | 2014-12-22 | 2016-03-31 | Upm Kymmene Corp | Nanofibrilliselluloosan hydrogeelin lämpökäsittely |
FI125883B (fi) | 2014-12-22 | 2016-03-31 | Upm Kymmene Corp | Katalyyttisesti hapetetun nanofibrilliselluloosan hydrogeelin käsittely |
FI127834B (fi) * | 2015-06-04 | 2019-03-29 | Upm Kymmene Corp | Prosessi nanofibrilliselluloosan hydrogeelin tuottamiseksi |
US11173130B2 (en) * | 2015-09-24 | 2021-11-16 | Massachusetts Eye And Ear Infirmary | Drug delivery system and methods of use |
WO2017123577A1 (en) * | 2016-01-12 | 2017-07-20 | Repros Therapeutics Inc. | Trans-clomiphene and progesterone receptor antagonist combination therapy for treating hormone-dependent conditions |
EP3481427A4 (en) * | 2016-07-08 | 2020-01-22 | Cellutech AB | MEDICINAL CARRIER WITH SOLID CELLULAR MATERIAL COMPRISING CELLULOSE NANOFIBERS (CNF), SOLID CELLULAR MATERIAL WITH CLOSED ALVEOLS |
JP7150603B2 (ja) * | 2016-08-08 | 2022-10-11 | 日本製紙株式会社 | セルロースナノファイバー分散液の評価方法 |
DK3335695T3 (da) * | 2016-12-15 | 2020-04-20 | Upm Kymmene Corp | Fremgangsmåde til frysetørring af hydrogel omfattende nanofibrillær cellulose, frysetørret medicinsk hydrogel omfattende nanofibrillær cellulose og hydrogel omfattende nanofibrillær cellulose |
EP3335696B1 (en) * | 2016-12-15 | 2019-12-18 | UPM-Kymmene Corporation | A method for drying cell-free tissue extract in a hydrogel comprising nanofibrillar cellulose and a dried hydrogel comprising nanofibrillar cellulose and cell-free tissue extract |
WO2019108887A1 (en) * | 2017-11-30 | 2019-06-06 | Warner Babcok Institute For Green Chemistry, Llc | Products comprising plant-based micro fibers |
KR102200787B1 (ko) * | 2017-12-29 | 2021-01-12 | 한경대학교 산학협력단 | 나노셀룰로오스를 이용한 습윤성 탄력붕대 |
EP3616730A1 (en) | 2018-08-28 | 2020-03-04 | UPM-Kymmene Corporation | Composition or matrix for storage of bacteriophages comprising nanofibrillar cellulose |
JP7147490B2 (ja) * | 2018-11-07 | 2022-10-05 | 凸版印刷株式会社 | 徐放性複合粒子、徐放性複合粒子の製造方法及び乾燥粉体 |
HUP1900226A1 (hu) * | 2019-06-21 | 2020-12-28 | Hummel Zoltan Dr | Hidrofil mikrobiális cellulóz nanorostokat tartalmazó hordozóanyag (gél) a bélnyálkahártya állapotának javítására |
EP3791864A1 (en) * | 2019-09-13 | 2021-03-17 | UPM-Kymmene Corporation | Method for preparing pharmaceutical composition and pharmaceutical composition |
EP3791858A1 (en) * | 2019-09-13 | 2021-03-17 | UPM-Kymmene Corporation | Injectable pharmaceutical formulation |
BR102020007749A2 (pt) * | 2020-04-17 | 2021-11-03 | Edson Luiz Peracchi | Implante subcutâneo reabsorvível de longa duração com liberação controlada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da endometriose |
WO2022118104A1 (en) | 2020-12-01 | 2022-06-09 | 3M Innovative Properties Company | Article for storage of bacteriophages and method thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04243819A (ja) * | 1991-01-25 | 1992-08-31 | Grelan Pharmaceut Co Ltd | 徐放性製剤 |
US5405953A (en) * | 1993-08-03 | 1995-04-11 | Biocontrol Incorporated | Microfibrillated oxycellulose |
JP4308336B2 (ja) * | 1997-03-14 | 2009-08-05 | 株式会社日本吸収体技術研究所 | ミクロフィブリル状微細繊維構造体およびその製造方法 |
WO2002022172A2 (en) * | 2000-09-14 | 2002-03-21 | University Of Iowa Research Foundation | Powdered/microfibrillated cellulose |
JP2006160626A (ja) * | 2004-12-03 | 2006-06-22 | Kyowa Hakko Kogyo Co Ltd | 徐放化方法 |
JP2006160627A (ja) * | 2004-12-03 | 2006-06-22 | Kyowa Hakko Kogyo Co Ltd | 時限放出化方法 |
US8951551B2 (en) | 2005-08-31 | 2015-02-10 | Board Of Regents, The University Of Texas System | Multiribbon nanocellulose as a matrix for wound healing |
CN101437594B (zh) * | 2006-02-13 | 2012-07-04 | 唐纳森公司 | 包括细纤维和反应、吸附或吸收颗粒的过滤网 |
CN101172164A (zh) * | 2006-11-03 | 2008-05-07 | 中国科学院化学研究所 | 可生物降解及吸收的生物高分子纳米纤维膜材料及其制法和用途 |
AU2008344471B2 (en) | 2007-12-28 | 2012-12-20 | Nippon Paper Industries Co., Ltd. | Processes for producing cellulose nanofibers, cellulose oxidation catalysts and methods for oxidizing cellulose |
US20100159046A1 (en) * | 2008-12-19 | 2010-06-24 | Xylos Corporation | Minimal tissue attachment implantable materials |
FI20095638A0 (fi) | 2009-06-09 | 2009-06-09 | Valtion Teknillinen | Hydrofobiineja aktiivisten aineiden dispergointiin |
FI123988B (fi) | 2010-10-27 | 2014-01-31 | Upm Kymmene Corp | Soluviljelymateriaali |
US8758826B2 (en) * | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
-
2011
- 2011-11-15 FI FI20116138A patent/FI130619B/fi active
-
2012
- 2012-11-15 EP EP12799232.9A patent/EP2779996B1/en active Active
- 2012-11-15 US US14/358,141 patent/US11389537B2/en active Active
- 2012-11-15 WO PCT/FI2012/051121 patent/WO2013072563A1/en active Application Filing
- 2012-11-15 JP JP2014541721A patent/JP6178329B2/ja active Active
-
2015
- 2015-03-23 HK HK15102889.3A patent/HK1202418A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
HK1202418A1 (en) | 2015-10-02 |
JP6178329B2 (ja) | 2017-08-09 |
EP2779996B1 (en) | 2024-04-10 |
JP2014533296A (ja) | 2014-12-11 |
EP2779996A1 (en) | 2014-09-24 |
US20140322327A1 (en) | 2014-10-30 |
WO2013072563A1 (en) | 2013-05-23 |
FI130619B (fi) | 2023-12-15 |
US11389537B2 (en) | 2022-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI20116138L (fi) | Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen | |
SMT201600271B (it) | BENZOSSAZEPINONI FUSI COME MODULATORI DI CANALl IONICI | |
DK2694038T3 (da) | Farmaceutisk sammensætning | |
CO6791604A2 (es) | Compuesto para liberación controlada de agentes de tratamiento de pozos | |
DK2787975T3 (da) | Robuste formuleringer med kontrolleret frigivelse | |
EP2714015A4 (en) | SOLID DOSAGE FORMS WITH CONTROLLED RELEASE | |
CO6801733A2 (es) | Silicato de zirconio microporoso para el tratamiento de la hipercalemia | |
BR112013022112A2 (pt) | composição | |
ZA201307862B (en) | Controlled release pharmaceutical dosage forms | |
BR112013022102A2 (pt) | composição | |
DK2686017T3 (da) | Oftalmisk sammensætning | |
BR112013029316A2 (pt) | micro-partícula injetável de liberação controlada | |
BR112014004395A2 (pt) | composição | |
DK3395357T3 (da) | Sammensætning til kontrolleret ovariestimulering | |
CO6900117A2 (es) | Formulaciones peptídicas de liberación controlada | |
DK2783152T3 (da) | Trykafgivelsessystem | |
BR112013033808A2 (pt) | composição | |
DE112012003251A5 (de) | Ausrücksystem | |
DE112012003262A5 (de) | Ausrücksystem | |
BR112015008572A2 (pt) | formulações de liberação modificada para oprozomib | |
ES2721400T8 (es) | Composición de Diclofenaco | |
BR112014009319A2 (pt) | compostos farmacêuticos | |
IL236465A0 (en) | Pharmaceutical composition for delayed release of active substances | |
BR112013031686A2 (pt) | fusão de moléculas bioativas | |
BR112014007030A2 (pt) | composição |